Pfizer CEO, Albert Bourla, said in nationally televised interview that it is necessary to fend off waning protection.
This article was originally published in ContagionLive.com
Yesterday, on the nationally broadcast television show, Face the Nation, Pfizer CEO Albert Bourla said he expected people to need a fourth dose of the vaccine to prevent another wave of COVID-19.
Back in January, a study published in The Lancet found that 3 doses of the Pfizer-BioNTech (BNT162b2) or AstraZeneca (AZD1222) COVID-19 vaccines effectively neutralized the Omicron variant.
However since the emergence of Omicron in the last few months, waning protection in the vaccines has been a developing issue as the case loads increased in the early part of 2022.
Pfizer has been working on a booster dose to address the variants.
"The variants are coming," Bourla said. "Omicron was the first to be able to evade in a skillful way the immune protection we were given, but we also know the duration of the protection doesn’t last very long. What we are trying to do—and we are working very diligently right now—is to not only make a vaccine that protects against all variants including Omicron but something that also protects for a year."
When asked if a fourth dose was necessary, Bourla said, ”It is necessary a fourth booster, right now; the protection we are getting from the third is good enough; it is actually quite good for hospitalizations and deaths; it’s not that good against infections.”
No timeline has been set for the booster dose for the variants yet, but Bourla says the company will be ready with the manufacturing whenever a decision is made.
In the same interview, he said we are going to have to learn how to live with the virus. When asked if he thought if the COVID-19 vaccine would need to be administered annually like the influenza vaccine Bourla said, “I think so."
The Key to Sterile Processing Success: Leadership Engagement and Team Collaboration
January 24th 2025Effective sterile processing leadership requires active engagement, clear communication, and a transformational approach to foster collaboration, accountability, and quality in infection prevention and surgical instrument management.
Evaluating Automated Dispensing Systems for Disinfectants in Hospitals
January 23rd 2025Hospitals rely on automated disinfectant dispensers, but a study led by Curtis Donskey, MD, found inconsistent dilution levels, with some dispensers releasing only water. Improved monitoring and design modifications are essential.
Alcohol-Based Antiseptics Show Promise for Nasal Decolonization and SSI Prevention
January 23rd 2025A meta-analysis found alcohol-based antiseptics significantly reduce Staphylococcus aureus-related surgical site infections (SSIs), demonstrating efficacy comparable to mupirocin and iodophor, supporting their expanded use in infection prevention strategies.
ASRA Pain Medicine Releases Groundbreaking Infection Control Guidelines for Pain Management
January 22nd 2025The American Society of Regional Anesthesia and Pain Medicine (ASRA Pain Medicine) released comprehensive infection control guidelines for pain procedures, emphasizing prevention, early recognition, multidisciplinary collaboration, and judicious antibiotic use to enhance patient safety and healthcare outcomes.